lenalidomide + bendamustine + prednisone

The combination of lenalidomide, bendamustine, and prednisone is an investigational regimen primarily studied for the treatment of relapsed or refractory multiple myeloma. Lenalidomide is an immunomodulatory agent that acts by altering cytokine production, enhancing T cell and NK cell function, and directly targeting malignant cells through modulation of the cereblon E3 ubiquitin ligase complex. Bendamustine is a bifunctional alkylating agent that induces DNA crosslinking leading to apoptosis in cancer cells. Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. This combination has demonstrated favorable safety and efficacy profiles in early-phase clinical trials for patients with advanced multiple myeloma who have failed prior therapies[1][3]. The regimen leverages distinct mechanisms of action from each component to achieve synergistic antitumor effects.